Manulife (Manufacturers Life Insurance)’s Corvus Pharmaceuticals CRVS Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Buy	101,779 +84,282	+482%	+$1.35M	﹤0.01%	1621
2025 Q4	$135K	Sell	17,497 -1,229	-7%	-$9.69K	﹤0.01%	2646
2025 Q3	$138K	Sell	18,726 -372	-2%	-$1.9K	﹤0.01%	2699
2025 Q2	$76.4K	Buy	+19,098	New	+$69.5K	﹤0.01%	2818
2018 Q3	–	Sell	-12,292	Closed	-$135K	–	3099
2018 Q2	$135K	Buy	12,292 +11,610	+1,702%	+$130K	﹤0.01%	3339
2018 Q1	$8K	Sell	682 -1,581	-70%	-$15K	﹤0.01%	3978
2017 Q4	$23K	Buy	2,263 +1,532	+210%	+$19.6K	﹤0.01%	3754
2017 Q3	$12K	Hold	731	–	–	﹤0.01%	3774
2017 Q2	$9K	Buy	731 +46	+7%	+$491	﹤0.01%	3805
2017 Q1	$14K	Hold	685	–	–	﹤0.01%	3595
2016 Q4	$10K	Hold	685	–	–	﹤0.01%	3763
2016 Q3	$11K	Buy	685 +574	+517%	+$8.27K	﹤0.01%	3666
2016 Q2	$2K	Buy	+111	New	+$1.5K	﹤0.01%	3982

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s CRVS Position: Q1 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Corvus Pharmaceuticals (CRVS) stake by 482% in Q1 2026, buying an estimated $1.35M and bringing the position to 101,779 shares worth $1.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1621.

Manulife (Manufacturers Life Insurance) first reported a position in CRVS in Q2 2016 and has held it in 13 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

Manulife (Manufacturers Life Insurance) held 101,779 shares of Corvus Pharmaceuticals worth $1.49M as of Q1 2026.
Manulife (Manufacturers Life Insurance) bought 84,282 Corvus Pharmaceuticals shares in Q1 2026, an estimated $1.35M.
Corvus Pharmaceuticals made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q1 2026, its #1621 holding.
Manulife (Manufacturers Life Insurance) first reported a position in Corvus Pharmaceuticals in Q2 2016 and has held it in 13 quarters since.
164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.